What types of cancer are capmatinib indicated for?

Capmatinib (Capmatinib) is an oral targeted therapy drug for MET gene abnormalities. It is mainly suitable for patients carrying MET exon 14 skipping mutation (MET exon 14 skipping patients with advanced or metastatic non-small cell lung cancer (NSCLC). The proportion of such mutations in NSCLC patients is low, accounting for about 3% to 4%, but once they occur, they are usually associated with more aggressive tumors and poorer prognosis. Capmatinib can specifically inhibit the activity of MET protein, thereby blocking the cell growth and metastasis signaling pathways triggered by it.

In addition to non-small cell lung cancer, MET gene abnormalities have also been found in a variety of solid tumors, including hepatocellular carcinoma, renal cancer, gastric cancer and other types. Although the current approved indications of capmatinib in China and most countries are mainly NSCLC, some clinical studies have been conducted around the world to explore its application potential in other tumor types. For example, MET amplification or overexpression exists in some patients with advanced liver cancer or gastric cancer, and ongoing studies are evaluating the efficacy of capmatinib in these populations.

Capmatinib has shown good anti-tumor activity in clinical trials, especially in patients who have not received other MET targeted therapies. The objective response rate is high, and some patients have significant tumor shrinkage and even complete remission cases. It is worth noting that capmatinib has also been confirmed to have certain central nervous system activity and may also produce a therapeutic response in patients with brain metastases, which is of great significance for patients with advanced NSCLC.

In general, the main indication for capmatinib currently approved is MET mutation-positive advanced non-small cell lung cancer, but with the deepening of research, its application prospects in other MET abnormality-related tumors are gradually emerging. In the future, if more clinical data confirms its effectiveness in other cancer types, the indications of capmatinib are expected to be further expanded, bringing new hope for precise targeted therapy to more tumor patients.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib